Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	The change in Forced Vital Capacity (FVC) (% predicted) at 6 months following treatment initiation with oral Pirfenidone versus placebo in patients with COVID-19 associated pulmonary fibrosisTimepoint: at 6 months	The change in Forced Vital Capacity (FVC) (% predicted) at 6 months following treatment initiation with oral Pirfenidone versus placebo in patients with COVID-19 associated pulmonary fibrosisTimepoint: at 6 months
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
May 27, 2021, 12:45 a.m.	oms	The change in Forced Vital Capacity (FVC) (% predicted) at 6 months following treatment initiation with oral Pirfenidone versus placebo in patients with COVID-19 associated pulmonary fibrosisTimepoint: at 6 months	The change in Forced Vital Capacity (FVC) (% predicted) at 6 months following treatment initiation with oral Pirfenidone versus placebo in patients with COVID-19 associated pulmonary fibrosisTimepoint: at 6 months